Drugs / MVA/HIV62
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00820846 | Jan 2009 → Aug 2012 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA/HIV62 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00820846 ↗ |
| Modality | Vaccine | “An rMVA vaccine strategy expresses both HIV and MVA proteins” NCT00820846 ↗ |